Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 745439, 7 pages
http://dx.doi.org/10.1155/2014/745439
Review Article

The Role of Magnesium in the Pathogenesis and Treatment of Glaucoma

1Department of Ophthalmology, Recep Tayyip Erdoğan University Medical School, 53020 Rize, Turkey
2Department of Ophthalmology, Duzce State Hospital, 81100 Duzce, Turkey
3Department of Ophthalmology, Sorgun State Hospital, 66700 Yozgat, Turkey
4Department of Ophthalmology, Yatağan State Hospital, 48500 Muğla, Turkey
5Department of Ophthalmology, Onsekizmart University Medical School, 17020 Canakkale, Turkey
6Department of Ophthalmology, Gazi University Medical School, 06560 Ankara, Turkey
7Department of Medical Pharmacology, Gazi University Medical School, 06560 Ankara, Turkey

Received 19 April 2014; Revised 25 June 2014; Accepted 16 July 2014; Published 13 October 2014

Academic Editor: Paolo Fogagnolo

Copyright © 2014 Feyzahan Ekici et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Weinreb and P. T. Khaw, “Primary open-angle glaucoma,” The Lancet, vol. 363, no. 9422, pp. 1711–1720, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Mozaffarieh and J. Flammer, “New insights in the pathogenesis and treatment of normal tension glaucoma,” Current Opinion in Pharmacology, vol. 13, no. 1, pp. 43–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Mozaffarieh and J. Flammer, “Is there more to glaucoma treatment than lowering IOP?” Survey of Ophthalmology, vol. 52, supplement 2, pp. S174–S179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. R. Lichter, D. C. Musch, B. W. Gillespie et al., “Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery,” Ophthalmology, vol. 108, no. 11, pp. 1943–1953, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. D. R. Anderson, S. M. Drance, and M. Schulzer, “Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma,” American Journal of Ophthalmology, vol. 136, no. 5, pp. 820–829, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. H. J. Kaiser, A. Schoetzau, D. Stumpfig, and J. Flammer, “Blood-flow velocities of the extraocular vessels in patients with high- tension and normal-tension primary open-angle glaucoma,” American Journal of Ophthalmology, vol. 123, no. 3, pp. 320–327, 1997. View at Google Scholar · View at Scopus
  7. J. E. Grunwald, J. Piltz, S. M. Hariprasad, and J. DuPont, “Optic nerve and choroidal circulation in glaucoma,” Investigative Ophthalmology and Visual Science, vol. 39, no. 12, pp. 2329–2336, 1998. View at Google Scholar · View at Scopus
  8. J. Flammer and S. M. Drance, “Reversibility of a glaucomatous visual field defect after acetazolamide therapy,” Canadian Journal of Ophthalmology, vol. 18, no. 3, pp. 139–141, 1983. View at Google Scholar · View at Scopus
  9. M. Cellini, G. L. Possati, N. Caramazza, V. Profazio, and R. Caramazza, “The use of flunarizine in the management of low-tension glaucoma: a color doppler study,” Acta Ophthalmologica Scandinavica, vol. 75, no. 224, pp. 57–58, 1997. View at Google Scholar · View at Scopus
  10. A. G. Boehm, K. A. Breidenbach, L. E. Pillunat, A. S. Bernd, M. F. Mueller, and A. U. Koeller, “Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 241, no. 1, pp. 34–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Shahsuvaryan, “Glaucomatous optic neuropathy management: the role of neuroprotective agents,” Medical Hypothesis, Discovery & Innovation Ophthalmology, vol. 2, no. 2, pp. 41–46, 2013. View at Google Scholar
  12. C. Mayama, “Calcium channels and their blockers in intraocular pressure and glaucoma,” European Journal of Pharmacology, vol. 739, pp. 96–105, 2013. View at Publisher · View at Google Scholar
  13. H. J. Kaiser, D. Stümpfig, and J. Flammer, “Short- Term effect of dipyridamole on blood flow velocities in the extraocular vessels,” International Ophthalmology, vol. 19, no. 6, pp. 355–358, 1995. View at Google Scholar · View at Scopus
  14. A. H. Neufeld, A. Sawada, and B. Becker, “Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 17, pp. 9944–9948, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Quaranta, S. Bettelli, M. G. Uva, F. Semeraro, R. Turano, and E. Gandolfo, “Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma,” Ophthalmology, vol. 110, no. 2, pp. 359–364, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Eckert, U. Keil, S. Kressmann et al., “Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress,” Pharmacopsychiatry, vol. 36, no. 1, pp. S15–S23, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. N.-E. L. Saris, E. Mervaala, H. Karppanen, J. A. Khawaja, and A. Lewenstam, “Magnesium: an update on physiological, clinical and analytical aspects,” Clinica Chimica Acta, vol. 294, no. 1-2, pp. 1–26, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. L. T. Iseri and J. H. French, “Magnesium: nature's physiologic calcium blocker,” American Heart Journal, vol. 108, no. 1, pp. 188–193, 1984. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Agarwal, L. Iezhitsa, and P. Agarwal, “Pathogenetic role of magnesium deficiency in ophthalmic diseases,” Biometals, vol. 27, no. 1, pp. 5–18, 2014. View at Publisher · View at Google Scholar
  20. R. J. Elin, “Magnesium: the fifth but forgotten electrolyte,” American Journal of Clinical Pathology, vol. 102, no. 5, pp. 616–622, 1994. View at Google Scholar · View at Scopus
  21. M. Barbagallo and L. J. Dominguez, “Magnesium and aging,” Current Pharmaceutical Design, vol. 16, no. 7, pp. 832–839, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Kupetsky-Rincon and J. Uitto, “Magnesium: novel applications in cardiovascular disease—a review of the literature,” Annals of Nutrition and Metabolism, vol. 61, no. 2, pp. 102–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. G. Huerta, J. N. Roemmich, M. L. Kington et al., “Magnesium deficiency is associated with insulin resistance in obese children,” Diabetes Care, vol. 28, no. 5, pp. 1175–1181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. Chang, W. J. Mack, J. L. Saver, and N. Sanossian, “Magnesium: potential roles in neurovascular disease,” Frontiers in Neurology, vol. 5, article 52, 2014. View at Publisher · View at Google Scholar
  25. C. G. Musso, “Magnesium metabolism in health and disease,” International Urology and Nephrology, vol. 41, no. 2, pp. 357–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Smith, R. F. Lowe, J. Fullerton, S. M. Currie, L. Harris, and E. Felker-Kantor, “An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management,” BMC Pregnancy and Childbirth, vol. 13, article 34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Gong, T. Amemiya, and K. Takaya, “Retinal changes in magnesium-deficient rats,” Experimental Eye Research, vol. 72, no. 1, pp. 23–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. K. H. Katsanos, M. Elisaf, E. Bairaktari, and E. V. Tsianos, “Severe hypomagnesemia and hypoparathyroidism in Kearns-Sayre syndrome,” The American Journal of Nephrology, vol. 21, no. 2, pp. 150–153, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Y. Liang and L. R. Lee, “Retinitis pigmentosa associated with hypomagnesaemia,” Clinical and Experimental Ophthalmology, vol. 38, no. 6, pp. 645–647, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Gong, Y. Takami, and T. Amemiya, “Ultrastructure of the optic nerve in magnesium-deficient rats,” Ophthalmic Research, vol. 35, no. 2, pp. 84–92, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Kirkpatrick, “The use of magnesium sulphate as a local application in inflammation of the conjunctiva and cornea,” British Journal of Ophthalmology, vol. 4, no. 6, p. 281, 1920. View at Google Scholar
  32. H. Gong, Y. Takami, T. Kitaoka, and T. Amemiya, “Corneal changes in magnesium-deficient rats,” Cornea, vol. 22, no. 5, pp. 448–456, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Thalasselis, H. F. Taie, J. Etchepareborda, and A. Selim, “Keratoconus, magnesium deficiency, type A behavior, and allergy,” The American Journal of Optometry and Physiological Optics, vol. 65, no. 6, pp. 499–505, 1988. View at Google Scholar · View at Scopus
  34. R. Agarwal, I. N. Iezhitsa, P. Agarwal, and A. A. Spasov, “Mechanisms of cataractogenesis in the presence of magnesium deficiency,” Magnesium Research, vol. 26, no. 1, pp. 2–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Hatwal, A. S. Gujral, R. P. S. Bhatia, J. K. Agrawal, and H. S. Bajpai, “Association of hypomagnesemia with diabetic retinopathy,” Acta Ophthalmologica, vol. 67, no. 6, pp. 714–716, 1989. View at Google Scholar · View at Scopus
  36. M. C. Grieshaber, M. Mozaffarieh, and J. Flammer, “What is the link between vascular dysregulation and glaucoma?” Survey of Ophthalmology, vol. 52, supplement 2, pp. S144–S154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Flammer and S. Orgül, “Optic nerve blood-flow abnormalities in glaucoma,” Progress in Retinal and Eye Research, vol. 17, no. 2, pp. 267–289, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. H. J. Kaiser and J. Flammer, “Systemic hypotension: a risk factor for glaucomatous damage?” Ophthalmologica, vol. 203, no. 3, pp. 105–108, 1991. View at Google Scholar · View at Scopus
  39. H. J. Kaiser, J. Flammer, T. Graf, and D. Stumpfig, “Systemic blood pressure in glaucoma patients,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 231, no. 12, pp. 677–680, 1993. View at Google Scholar · View at Scopus
  40. M. Nakabayashi, “Review of the ischemia hypothesis for ocular hypertension other than congenital glaucoma and closed-angle glaucoma,” Ophthalmologica, vol. 218, no. 5, pp. 344–349, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Flammer, K. Konieczka, and A. J. Flammer, “The primary vascular dysregulation syndrome: implications for eye diseases,” The EPMA Journal, vol. 4, no. 1, article 14, 2013. View at Publisher · View at Google Scholar
  42. J. Flammer, I. O. Haefliger, S. Orgül, and T. Resink, “Vascular dysregulation: a principal risk factor for glaucomatous damage?” Journal of Glaucoma, vol. 8, no. 3, pp. 212–219, 1999. View at Google Scholar · View at Scopus
  43. J. Wierzbowska, R. Wierzbowski, A. Stankiewicz, B. Siesky, and A. Harris, “Cardiac autonomic dysfunction in patients with normal tension glaucoma: 24-h heart rate and blood pressure variability analysis,” British Journal of Ophthalmology, vol. 96, no. 5, pp. 624–628, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Gugleta, S. Orgül, P. W. Hasler, T. Picornell, D. Gherghel, and J. Flammer, “Choroidal vascular reaction to hand-grip stress in subjects with vasospasm and its relevance in glaucoma,” Investigative Ophthalmology and Visual Science, vol. 44, no. 4, pp. 1573–1580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Landsberg, “Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome,” Annals of the New York Academy of Sciences, vol. 892, pp. 84–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. R. M. K. Stewart and L. G. Clearkin, “Insulin resistance and autoregulatory dysfunction in glaucoma and retinal vein occlusion,” The American Journal of Ophthalmology, vol. 145, no. 3, pp. 394–396, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. S. W. Oh, S. Lee, C. Park, and D. J. Kim, “Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 5, pp. 434–440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sjogren, C.-H. Floren, and A. Nilsson, “Magnesium deficiency in IDDM related to level of glycosylated hemoglobin,” Diabetes, vol. 35, no. 4, pp. 459–463, 1986. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Le, B. N. Mukesh, C. A. McCarty, and H. R. Taylor, “Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project,” Investigative Ophthalmology and Visual Science, vol. 44, no. 9, pp. 3783–3789, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. S. de Voogd, M. K. Ikram, R. C. W. Wolfs et al., “Is diabetes mellitus a risk factor for open-angle glaucoma?. The Rotterdam study,” Ophthalmology, vol. 113, no. 10, pp. 1827–1831, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. J. M. Tielsch, J. Katz, H. A. Quigley, J. C. Javitt, and A. Sommer, “Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey,” Ophthalmology, vol. 102, no. 1, pp. 48–53, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Y. Lee, H. L. Park, C. K. Park, and M. D. Ahn, “Analysis of systemic endothelin-1, matrix metalloproteinase-9, macrophage chemoattractant protein-1, and high-sensitivity C-reactive protein in normal-tension glaucoma,” Current Eye Research, vol. 37, no. 12, pp. 1121–1126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. I. Leibovitch, S. Kurtz, A. Kesler, N. Feithliher, G. Shemesh, and B. Sela, “C-reactive protein levels in normal tension glaucoma,” Journal of Glaucoma, vol. 14, no. 5, pp. 384–386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Gathwala, “Neuronal protection with pagnesium,” Indian Journal of Pediatrics, vol. 68, no. 5, pp. 417–419, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. G. Tezel, “Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences,” Progress in Retinal and Eye Research, vol. 25, no. 5, pp. 490–513, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. A. H. Neufeld, R. Hemandez, and M. Gonzalez, “Nitric oxide synthase in the human glaucomatous optic nerve head,” Archives of Ophthalmology, vol. 115, no. 4, pp. 497–503, 1997. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Retamal, S. Yin, G. A. Altenberg, and L. Reuss, “Modulation of Cx46 hemichannels by nitric oxide,” American Journal of Physiology—Cell Physiology, vol. 296, no. 6, pp. C1356–C1363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Z. Shoshani, A. Harris, M. M. Shoja et al., “Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma,” Current Eye Research, vol. 37, no. 1, pp. 1–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Noske, J. Hensen, and M. Wiederholt, “Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 235, no. 9, pp. 551–552, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Prasanna, R. Krishnamoorthy, A. F. Clark, R. J. Wordinger, and T. Yorio, “Human optic nerve head astrocytes as a target for endothelin-1,” Investigative Ophthalmology and Visual Science, vol. 43, no. 8, pp. 2704–2713, 2002. View at Google Scholar · View at Scopus
  61. E. S. Dettmann, T. F. Lüscher, J. Flammer, and I. O. Haefliger, “Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 236, no. 1, pp. 47–51, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Orgul, G. A. Cioffi, D. J. Wilson, D. R. Bacon, and E. M. Van Buskirk, “An endothelin-1 induced model of optic nerve ischemia in the rabbit,” Investigative Ophthalmology & Visual Science, vol. 37, no. 9, pp. 1860–1869, 1996. View at Google Scholar
  63. N. Toriu, M. Sasaoka, M. Shimazawa, T. Sugiyama, and H. Hara, “Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits,” Journal of Ocular Pharmacology and Therapeutics, vol. 17, no. 2, pp. 131–149, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. C. R. DeWitt and J. C. Waksman, “Pharmacology, pathophysiology and management of calcium channel blocker and β-blocker toxicity,” Toxicological Reviews, vol. 23, no. 4, pp. 223–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Shechter, M. Sharir, M. J. Paul et al., “Oral magnesium therapy improves endothelial function in patients with coronary artery disease,” Circulation, vol. 102, no. 19, pp. 2353–2358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. R. M. Touyz, “Role of magnesium in the pathogenesis of hypertension,” Molecular Aspects of Medicine, vol. 24, no. 1–3, pp. 107–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Laurant and A. Berthelot, “Endothelin-1-induced contraction in isolated aortae from normotensive and DOCA-salt hypertensive rats: effect of magnesium,” British Journal of Pharmacology, vol. 119, no. 7, pp. 1367–1374, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Ishiguro, T. Matsuyama, H. Sakaguchi, and A. Nishio, “Ex vivo study of the increased sensitivity to NO of endothelium-denuded thoracic aortas isolated from dietary magnesium-deficient rats,” Magnesium Research, vol. 10, no. 1, pp. 21–31, 1997. View at Google Scholar · View at Scopus
  69. M. Barbagallo, L. J. Dominguez, A. Galioto, A. Pineo, and M. Belvedere, “Oral magnesium supplementation improves vascular function in elderly diabetic patients,” Magnesium Research, vol. 23, no. 3, pp. 131–137, 2010. View at Google Scholar · View at Scopus
  70. Z. W. Yang, A. Gebrewold, M. Nowakowski, B. T. Altura, and B. M. Altura, “Mg2+-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 278, no. 3, pp. R628–R639, 2000. View at Google Scholar · View at Scopus
  71. S. Shareef, A. Sawada, and A. H. Neufeld, “Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure,” Investigative Ophthalmology and Visual Science, vol. 40, no. 12, pp. 2884–2891, 1999. View at Google Scholar · View at Scopus
  72. W. B. Thoreson and P. Witkovsky, “Glutamate receptors and circuits in the vertebrate retina,” Progress in Retinal and Eye Research, vol. 18, no. 6, pp. 765–810, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. C. K. Vorwerk, S. A. Lipton, D. Zurakowski, B. T. Hyman, B. A. Sabel, and E. B. Dreyer, “Chronic low-dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine,” Investigative Ophthalmology and Visual Science, vol. 37, no. 8, pp. 1618–1624, 1996. View at Google Scholar · View at Scopus
  74. V. Chrysostomou, F. Rezania, I. A. Trounce, and J. G. Crowston, “Oxidative stress and mitochondrial dysfunction in glaucoma,” Current Opinion in Pharmacology, vol. 13, no. 1, pp. 12–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Lee, M. S. Shim, K. Y. Kim et al., “Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma,” Investigative Ophthalmology & Visual Science, vol. 55, no. 2, pp. 993–1005, 2014. View at Google Scholar
  76. A. Novelli, J. A. Reilly, P. G. Lysko, and R. C. Henneberry, “Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced,” Brain Research, vol. 451, no. 1-2, pp. 205–212, 1988. View at Publisher · View at Google Scholar · View at Scopus
  77. N. J. Sucher, S. A. Lipton, and E. B. Dreyer, “Molecular basis of glutamate toxicity in retinal ganglion cells,” Vision Research, vol. 37, no. 24, pp. 3483–3493, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. N. J. Sucher, S. Z. Lei, and S. A. Lipton, “Calcium channel antagonists attenuate NMDA receptor-mediated neurotoxicity of retinal ganglion cells in culture,” Brain Research, vol. 551, no. 1-2, pp. 297–302, 1991. View at Publisher · View at Google Scholar · View at Scopus
  79. B. J. Mills, R. D. Lindeman, and C. A. Lang, “Magnesium deficiency inhibits biosynthesis of blood glutathione and tumor growth in the rat,” Proceedings of the Society for Experimental Biology and Medicine, vol. 181, no. 3, pp. 326–332, 1986. View at Publisher · View at Google Scholar · View at Scopus
  80. M. E. Szabo, M. T. Droy-Lefaix, M. Doly, and P. Braquet, “Ischaemia- and reperfusion-induced Na+, K+, Ca2+ and Mg2+ shifts in rat retina: effects of two free radical scavengers, SOD and EGB 761,” Experimental Eye Research, vol. 55, no. 1, pp. 39–45, 1992. View at Google Scholar · View at Scopus
  81. R. A. Alberty, “Effect of pH and metal ion concentration on the equilibrium hydrolysis of adenosine triphosphate to adenosine diphosphate.,” Journal of Biological Chemistry, vol. 243, no. 7, pp. 1337–1343, 1968. View at Google Scholar · View at Scopus
  82. G. A. George and F. W. Heaton, “Changes in cellular composition during magnesium deficiency,” Biochemical Journal, vol. 152, no. 3, pp. 609–615, 1975. View at Google Scholar · View at Scopus
  83. A. Z. Gaspar, P. Gasser, and J. Flammer, “The influence of magnesium on visual field and peripheral vasospasm in glaucoma,” Ophthalmologica, vol. 209, no. 1, pp. 11–13, 1995. View at Publisher · View at Google Scholar · View at Scopus
  84. B. Aydin, M. Önol, A. Hondur et al., “The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma,” European Journal of Ophthalmology, vol. 20, no. 1, pp. 131–135, 2010. View at Google Scholar · View at Scopus